Last updated: 2026-10-13 21:14:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
IDEAYA Biosciences, Inc. (IDYA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34.30, with a market capitalisation of $3.48B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $26.20 to $42.68. This page covers its latest market performance, valuation, price trends and company information.
$3.48B | |
$36.06 | |
$47.74 | |
$2.95 | |
$36.06 | |
741.20K | |
769.24K | |
-- | |
$42.68 | |
$26.20 | |
-- | |
-- |
IDEAYA Biosciences, Inc. (IDYA) is trading at $34.29 in after-hours trading as of 2026-10-13 20:27:00, down 4.92% ($1.78) from the regular-session close of $36.06.
After-hours trading shows how investors are pricing IDYA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, IDEAYA Biosciences, Inc. (IDYA) moved from $37.36 to $34.30, representing a decline of 8.19% ($3.06).
The stock traded between $34.27 and $38.57 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 611.55 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 49.2%
IDYA is currently trading at $34.30, placing it 49.2% of the way from its 52-week low of $26.20 to its 52-week high of $42.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 145 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of IDEAYA Biosciences, Inc. (IDYA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.